The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: Review and recommendations for avoiding adverse drug interactions

Supportive Care in Cancer

Volumn 15, Issue 3, 2007, Pages 251-257

  Haddad, Abdo ^a   Davis, Mellar ^a,b   Lagman, Ruth ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adverse drug interactions; Cancer patients; Cytochrome system; Palliative medicine

Indexed keywords

ALPRAZOLAM; ANTIRETROVIRUS AGENT; BENZODIAZEPINE; BUPRENORPHINE; CARBAMAZEPINE; CASPOFUNGIN; CIPROFLOXACIN; CITALOPRAM; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DIAZEPAM; DILTIAZEM; ERYTHROMYCIN; FENTANYL; FLUCONAZOLE; FLUOXETINE; HALOPERIDOL; ITRACONAZOLE; KETOCONAZOLE; METHADONE; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SERTRALINE; TRIAZOLE; UNINDEXED DRUG; VENLAFAXINE; VORICONAZOLE;

CANCER; CANDIDEMIA; COMORBIDITY; DELIRIUM; DRUG CHOICE; DRUG METABOLISM; ENZYME ACTIVITY; GENETICS; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; KINETICS; MYCOSIS; NAUSEA; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEDATION; SIDE EFFECT; VOMITING; WITHDRAWAL SYNDROME;

ADRENAL CORTEX HORMONES; ANALGESICS, OPIOID; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PALLIATIVE CARE;

EID: 33847109783     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0127-5     Document Type: Review

References (47)

1. Curtis EB, Walsh TD (1993) Prescribing practices of a palliative care service. J Pain Symptom Manage 8(5):312-316
2. Richelson E (1998) Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. J Clin Psychiatry 59(Suppl 10):22-26
3. Lippincott's Pharmacology 2nd edition
4. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG (2001) cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386-392
5. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW et al (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42
6. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30(8):883-891
7. Schuetz E (2004) Lessons from the CYP3A4 promoter. Mol Pharmacol 65:279-281
8. Finta C, Zaphiropoulos P (2000) The human cytochromeP450 3A locus. Gene evaluation by capture of downstream exons. Gene 260:13-23
9. Spina E, Scordo MG, D'Arrigo C (2003) Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17(5):517-538
10. Ito K, Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22(1):103-112
11. Ito K, Iwatsubo T (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together binding and transport. Annu Rev Pharmacol Toxicol 38:461-499
12. Von Moltke L, Greenblatt DJ, Schmider J, Wright E (1998) In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113-122
13. Galetin A, Ito K, Hallifax D, Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interaction. J Pharmacol Exp Ther 314(1):180-190
14. Houston JB, Galetin A (2005) Modeling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 433:351-360
15. Hunt CM, Westerkam WR, Stave GM (1992) Effect of age and gender on the activity of human hepatic CYP3A4. Biochem Pharmacol 44:275-283
16. Shapiro L, Shear N (2002) Drug interactions: proteins, pump, and P-450s. J Am Acad Dermatol 47(4):467-484
17. Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwohner K, Schulenberg D, Radbruch L (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18(2):100-107
18. Shaji K, Takashi I (1999) Pharmacokinetics of Haloperidol. Clin Pharmacokinet 37(6):435-456
19. Jann MW, Ereshefsky L, Saklad SR et al (1985) Effect of Carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 5:106-109
20. Arana GW, Goff DC, Friedman H et al (1986) Does Carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry 143:650-651
21. Goff DC, Midha KK, Brotman AW et al (1991) Elevation of plasma concentration of haloperidol after the addition of fluoxetine. Am J Psychiatry 148:790-792
22. Syvälahti EKG, Taiminen T, Saarijärvi S et al (1997) Citalopram causes no significant alteration in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 25:24-32
23. Lee MS, Kim YK, Lee SK et al (1998) A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 18:399-403
24. Herrlin K, Segerdahl M, Gustafsson LL, Kalso E (2000) Methadone, ciprofloxacin, and adverse drug reactions. Lancet 356(9247):2069-2070
25. Mclellan RA, Drobitch RK, Monshouwer M, Renton KW (1996) Fluoroquinlone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 36:1134-1138
26. Ferrari A, Coccia CP, Bertolini A, Sternieri E (2004) Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 50(6):551-559
27. Westphal JF (2000) Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50(4):285-295
28. Hersh EV, Moore PA (2004) Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc 135(3):298-311
29. Davis R, Markham A, Balfour J (1996) Ciprofloxacin: an update review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51:1019-1074
30. Aminimanizani A, Beringer P, Jelliffe R (2001) Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 40(3):169-187
31. Johnson RE, Fudala PJ, Payne R (2005) Buprenorphine: considerations for pain management. J Pain Symptom Manage 29(3):297-326
32. Katz HI (1999) Drug interactions of the newer oral antifungal agents. Br J Dermatol 141(Suppl 56):26-32
33. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB (2003) Voriconazole. Clin Ther 25(5):1321-1381
34. Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols D (2003) No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br J Clin Pharmacol 56(Suppl 1):30-36
35. Purkins L, Wood N, Kleinermans D, Love ER (2003) No clinically significant pharmacokinetic between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 56 (Suppl 1):62-68
36. Boucher H, Groll A, Chiou C, Walsh T (2004) Newer systemic antifungal agents pharmacokinetics, saftey and efficacy. Drugs 64(18):1997-2020
37. Groll AH, Walsh TJ (2001) Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Ivestig Drugs 10(8):1545-1558
38. Pessayre D, Larrey D, Funck-Brentano C et al (1985) Drug interactions and Hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 16(Suppl A):181-194
39. Von Rosensteil NA, Adam D (1995) Macrolide antibacterials. Drug interactions of clinical significant. Drug Safety 13(2):105-122
40. Sonne J, Dossing M, Loft S, Anderson PB (1985) Antipyrine clearance in pneumonia. Clin Pharmacol Ther 37:701-703
41. Von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI (1995) Metabolism of drug by P450, 3A isoforms. Clin Pharmacokinet 29(Suppl 1):33-44
42. Richelson E (2000) Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 75(9):933-942
43. Czock D, Keller F, Rasche FM, Häussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered Glucocorticoids. Clin Pharmacokinet 44(1):61-98
44. Sparreboom A, Cox MC, Acharya MR, Figg WD (2004) Herbal remedies in the united states: potential adverse interactions with anticancer agents. J Clin Oncol 22(12):2489-2503
45. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St. John wort (hypericum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54:349-356
46. Westphal JF (2000) Macrolide-induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50(4):285-295
47. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44(3):279-304